Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Table 3 Pharmacokinetic parameters following administration of the first dose of 150 mg or 2 mg/kg canakinumab

Patient	Dose (mg)	C_max (μg/mL)	T_max (d)	AUC_0-∞ (μgd/mL)	t_1/2 (d)	*CL/F*(L/d)	*Vz/F*(L)	*CL/F/wt*(L/d)/kg
1	34.8	NE	NE	NE	NE	NE	NE	NE
2	36.0	13.6	6.96	580	25.7	0.0621	2.3	0.0034
3	46.6	7.67	2	NE	NE	NE	NE	NE
4	48.0	NE	NE	NE	NE	NE	NE	NE
5	71.0	12.4	2	543	23.7	0.131	4.48	0.0037
6	150.0	16.3	7.05	647	22.9	0.232	7.67	0.0048
7	150.0	10.4	2.16	NE	NE	NE	NE	NE

NE: : non-estimable
C_max, Maximum (peak) serum drug concentration after drug administration; T_max, Time to reach peak or maximum concentration following drug administration; AUC0∞, Area under the concentration-time curve from time zero to infinity; t_1/2, The elimination half-life associated with the terminal slope (λz) of a semi logarithmic concentration-time curve; CL/F, The apparent total clearance from serum; Vz/F, The apparent volume of distribution during terminal phase